Canary Speech Partners with NeuroLexIQ

Canary Speech, a provider of voice biomarker technology, has partnered with NeuroLexIQ to bring objective, voice-based concussion screening into the client's first intake call for personal injury lawsuits.

The collaboration integrates Canary Speech's voice analysis directly into NeuroLexIQ's client intake workflow. During a structured intake conversation, often before any medical exam has taken place, the platform analyzes subtle patterns in speech to generate a concussion probability report. When that report flags a potential injury, it opens the door to qEEG validation, pairing voice-derived signals with FDA-cleared neurodiagnostic data to build a single, litigation-ready record.

"For the past decade, we've done the hard work of turning voice into a clinically meaningful signal," said Henry O'Connell, CEO of Canary Speech, in a statement. "In personal injury cases, timing is everything. Partnering with NeuroLexIQ lets us put that signal to work at the exact moment it can do the most good."

"By adding Canary Speech's voice analysis to our intake process, we can objectively identify potential brain injuries from the first conversation and route the right cases for qEEG testing before symptoms fade and causation becomes harder to establish," said Mark Slaughter, founder and CEO of NeuroLexIQ, in a statement. "It's a meaningful step forward for how our industry documents and supports these clients."